Hosted on MSN30m
Takeda-backed Ascentage Pharma sets terms for $170M IPOThe company has a licensing agreement with Innovent (OTCPK:IVBIY) (OTCPK:IVBXF) and collaborations with Pfizer (PFE), Merck (MRK) and AstraZeneca (AZN). The company's lead product, olverembatinib, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback